Online inquiry

IVTScrip™ mRNA-Anti-GLP1R, HM-12525A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8297MR)

This product GTTS-WQ8297MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets GLP1R gene. The antibody can be applied in Type 2 diabetes (T2 DM) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002062.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2740
UniProt ID P43220
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GLP1R, HM-12525A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8297MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ14905MR IVTScrip™ mRNA-Anti-stx2 A-subunit, Shigamabs®(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ6226MR IVTScrip™ mRNA-Anti-RABVgp4, CR4098(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CR4098
GTTS-WQ6848MR IVTScrip™ mRNA-Anti-IL3RA, DT-IL-3(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA DT-IL-3
GTTS-WQ4453MR IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-901608
GTTS-WQ15238MR IVTScrip™ mRNA-Anti-CD38, TAK-079(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA TAK-079
GTTS-WQ10375MR IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY2062430
GTTS-WQ5087MR IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CAM-3001
GTTS-WQ7191MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW